Aims/hypothesis. Glutamic acid decarboxylase 65 is a major autoantigen in Type I (insulin-dependent) diabetes mellitus, autoimmune polyendocrine syndrome and stiff-man syndrome. These disorders are characterised by the presence of multiple autoantibodies to the autoantigen which can be distinguished in a variety of different ways. We have investigated the role of single amino-acid mutations in glutamic acid decarboxylase 65 in distinguishing the binding of serum antibodies and a variety of patient-derived human IgG monoclonal antibodies directed to different determinants of the autoantigen. Methods. We identified a mutant of glutamic acid decarboxylase 65 that contained four single amino-acid mutations from the wild-type molecule. The role of these mutations was investigated by site-directed mutagenesis. We investigated the binding of patientderived serum antibodies to glutamic acid decarboxylase 65 to a number of single and double amino-acid mutants using immunoprecipitation with labelled, recombinant antigen. To overcome the heterogeneity of different anti-glutamic acid decarboxylase 65 antibodies present in a patient's serum, the binding of a panel of eleven patient-derived human monoclonal antibodies recognising different determinants on the autoantigen was also studied.
those recognised in other disorders. Single or double amino-acid replacements Asn247Ser and Leu574Pro in the autoantigen showed differential affects on expression of epitopes recognised by the human monoclonals. The double replacement of Asn247Ser and Leu574Pro in glutamic acid decarboxylase 65 resulted in the loss of binding of all eleven human monoclonal antibodies, irrespective of their epitope recognition. In contrast, single replacement of Leu574Pro statistically significantly reduced the binding of some carboxyl terminal-directed antibodies such as MICA 1, MICA 3 and DP-A without influencing the binding of other monoclonals. Replacement of Asn247Ser did not, however, influence the binding of any patients serum or human monoclonal antibodies. Conclusion/interpretation. Two distantly spaced amino acids, Asn247 and Leu574 in glutamic acid decarboxylase 65 were identified that act in concert to greatly influence the conformational structure of the autoantigen and statistically significantly influence the binding of antibodies present in Type I diabetic sera. The single or double amino-acid mutants can be used to distinguish some anti-glutamic acid decarboxylase-65 autoantibodies and could prove useful in distinguishing Type I diabetic from autoimmune polyendocrine syndrome and stiff-man syndrome patients' sera as well as to study changes in antibody patterns during disease progression. [Diabetologia (2000) 43 : 881±889]
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The enzyme glutamic acid decarboxylase (GAD) is responsible for the synthesis of the major inhibitory neurotransmitter, g-aminobutyric acid (GABA) [1] . Two related isomers GAD 65 and GAD 67 , encoded by non-allelic genes and sharing an identical exon-intron structure have been described [2±4] . The GAD isomers are expressed predominantly in the GABA-ergic neurons of the central nervous system and in pancreatic islet beta cells, although there are species differences in their expression in the islet beta cells [1, 5] . At the protein level, GAD 65 (of 585 residues) and GAD 67 (of 594) residues are highly dissimilar in the amino terminal 100 residues with a 25 % homology whereas the remainder of the molecule shows around 75 % homology [2, 3] .
Glutamic acid decarboxylase is also a major target in autoimmunity, with autoantibodies being present in new-onset Type I (insulin-dependent) diabetes mellitus, autoimmune polyendocrine syndrome (APS) and stiff-man syndrome (SMS) patients, where they serve as important markers of disease activity [6±14] . Autoantibodies to GAD in new-onset Type I diabetic patients are specifically directed to the GAD 65 ; a small proportion of antibodies to the larger isoform GAD 67 are also present but these can be blocked with GAD 65 indicating there are shared determinants between the molecules [15, 16] . Autoantibodies to GAD 65 are present in 70±80 % of new-onset Type I diabetic patients but their titre is considerably lower than those in APS and SMS patients [17±20] . There are also other differences between the anti-GAD 65 antibodies present in the sera from new-onset Type I diabetic patients and that from patients with APS and SMS. For example, anti-GAD 65 antibodies from Type I diabetic patients generally do not react with linear peptide sequences or with denatured antigen and thus are dependent on binding to discontinous determinants brought together in the three-dimensional folding of the protein [6, 18±24] . Furthermore, antibodies present in APS and SMS sera inhibit the enzymatic activity of GAD 65 but the antibodies in Type I diabetic sera do not show this property [25, 26] .
The determinants recognised by the anti-GAD 65 antibodies present in new-onset Type I diabetic patients have been delineated using chimeras of GAD 65 and GAD 67 [16, 21, 22] . The antibodies target epitopes in the middle region (residues 240 to 435) and the carboxyl terminal region (residues 451 to 570) of GAD 65 , termed IDDM-E1 and IDDM-E2, respectively [21, 22] . These and other studies using human monoclonal antibodies (hmABs) to GAD 65 from patients indicate that the epitope recognition of GAD 65 in new-onset Type I diabetic patients is diverse, with recognition of multiple determinants on the molecule [27±32] . Although the structure of GAD is not known, in a recent study a model was built of the middle (residues 200 to 460) and the carboxyl region (residues 461 to 585) of GAD 65 based on the three-dimensional structures of related decarboxylases and the autoreactive determinants recognised by the hmABs were fine mapped [33] . The model shows that the middle and carboxyl regions form two very separate folding domains where virtually the entire surface of GAD 65 is targeted by the autoimmune response [33] . In this study we report on single amino-acid mutagenesis analysis of GAD 65 to define the determinants recogised by hmABs to GAD 65 . The results identify two amino-acid replacements in GAD 65 that seem to act together in a concerted manner to ablate the binding of a variety of hmABs directed to different determinants of the molecule.
Materials and methods
Patients' sera and human IgG monoclonal antibodies to GAD 65 . Sera from new-onset Type I diabetic, APS and SMS patients were obtained after informed consent of the patients and ethical approval from the institution was given. Sera were obtained from new-onset Type I diabetic patients when the patients were first seen in the clinic or within 4 weeks of clinical diagnosis. Patients with APS were diagnosed on the criteria of islet-cell antibody positivity, absence of diabetes and documented presence of two other organ-specific autoantibodies [34] . Stiff-man syndrome was diagnosed according to clinical symptoms and none of these patients had diabetes. Only GAD antibody-positive sera (assay validated in the 2nd International GAD antibody workshop with a sensitivity of 87 % and a specificity of 91 %) [35] were included in these studies. A total of eleven hmABs to GAD 65 were used for immunoprecipitation; these comprised MICA 1, MICA 2, MICA 3, MICA 4, MICA 6, DP A, DP B, DP C, DP D, b78 and b96 [27, 29, 31] and were used as antibody-containing tissue culture supernatants. The b96 antibody used in this study was derived from the B cell line and recognises the C-terminal region of GAD 65 [31, 32] ; subsequent cloning of the cell line produced the b96.11 clone which recognises the middle region of GAD 65 with similar epitope recognition to MICA 4 [33] but this clone was not used in this study.
Cloning of GAD from human islet cells. Total RNA was prepared from 10 000 pelleted and purified human islet cells (from Professor RG Bretzel, Giessen, Germany). We did PCR for GAD 65 cDNA with the primers 5 ¢TCTCCGGATCCGATG GCATCTCCGGCTCT3 ¢ (BQ0) and 5 ¢GAGCAGAATTCTTATAAATCTTGTCCAAG-GC3 ¢ (BQ1) (containing EcoRI and a Bam HI sites, respectively) using 2.5 U Taq polymerase (Bioline, London, UK) for 30 cycles (40 s at 92°C, 90 s for 55°C and 240 s at 72°C). The faint band at 1.8 kb was purified and re-amplified as above using BQ0/BQ1 primers and two internal primers flanking the unique Nar1 site in GAD 65 (primer A, 5 ¢GGCAGACATGGCTGACATCAAC3 ¢ and primer B, 5 ¢TTCTGTTTGGCTTCAAG AAT3 ¢) and subcloned into Bluescript (pBS) (Stratagene, Cambridge, UK). Sequencing of the full-length GAD 65 cDNA showed that the clone contained eight single base-pair changes from the wild-type sequence (Table 1) . Of the base-pair alterations four were silent mutations; the other base-pair changes resulted in the following changes; Trp9Arg, Asn247Ser, Tyr425Asn and Leu574Pro (Table 1) . We cloned GAD 67 cDNA as described [31] .
Site-directed mutagenesis. To simplify the mutation nomenclature, the four amino-acid mutations in the mutant GAD 65 , Trp9Arg, Asn247Ser, Tyr425Asn and Leu574Pro were termed mutations A, B, C and D, respectively (Table 1) . Thus, we have denoted the mutant GAD 65 with all four mutations mutant GAD 65 /ABCD. The mutant GAD 65 was subcloned into pALTER-1 (Promega, Southampton, UK) and site-directed mutagenesis was done using the Altered Sites II kit (Promega) according to the manufacturer's instructions. The mutagenic oligonucleotides are shown in Fig. 1 and the presence of the desired mutations confirmed by DNA sequencing. To analyse the role of each of the four alterations in mutant GAD 65 /ABCD, a number of mutagenesis reactions were done in which one, two or three of the alterations in the mutant were reverted back to the wild-type amino acids. For example, GAD 65 containing only the single amino-acid mutation D was generated by reverting amino acids A, B and C in the mutant GAD 65 /ABCD to wild-type residues. This mutant was termed mutant GAD 65 /D. Similarly, the double mutant containing only mutation B and mutation D was generated by reverting residues A and C to wild-type residues and termed mutant GAD 65 /BD.
Antibody analysis. Wild-type GAD 65 and all mutant GAD 65 cDNAs were subcloned into pGEM4-Z (Promega) and protein produced by transcription translation in vitro in a singletube reaction using a TNT T7 quick-rabbit reticulocyte lysate system in the presence of 35 S-methionine. The size of all translated proteins was confirmed by SDS polyacrylamide gel electrophoresis and autoradiography. The expression of translated products of wild-type GAD 65 , GAD 67 and all mutant GAD 65 was monitored using serum from an SMS patient containing high-titre anti-GAD 65 antibodies. The conformational stability of the translated products was confirmed by reactivity with a panel of GAD 65 antibody-positive sera from Type I diabetic patients. All translated products gave similar reactivity to control antibodies when either used freshly prepared (without freezing) in shorter incubations or after freezing and in overnight incubations with antibodies. Immunoprecipitations were done at 4±7°C in 96-well microtitre plates using MultiScreen filtration plates (Millipore, Watford, UK) as described [36] . Data presented for human sera and hmABs are the mean of duplicate samples. Background binding [binding to 20 normal healthy control sera, GAD antibody negative culture supernatants or protein A Sepharose alone (Amersham-Pharmacia Biotech, Little Chalfont, UK)] was subtracted from the binding of the serum or hmAB-containing culture supernatant. C-glutamic acid as described [39] and compared with the activity of wildtype GAD 65 .
Results
Cloning of mutant GAD 65 . We cloned GAD 65 from human islet total cDNA by double PCR amplification from total human islet cDNA. Sequencing of both strands showed eight base-pair alterations from the published sequence, with four of these alterations leading to a change in the amino acids Trp9Arg (mutation A), Asn247Ser (mutation B), Tyr425Asn (mutation C) and Leu574Pro (mutation D) [2, 3] (Table 1). This mutant was termed mutant GAD 65 / ABCD. We investigated whether the mutant GAD 65 /ABCD arose as a result of incorrect basepair incorporation by the Taq polymerase [40] during the PCR reaction. The sequences around three of the base-pair alterations, nucleotides 740 (mutation B), 1273 (mutation C) and 1721 (mutation D) were amplified using the original stock of human islet cDNA used in the cloning of mutant GAD 65 . Sequencing of more than ten independent clones of each of the mutants showed a complete concordance of the sequence with wild-type GAD 65 giving confirmatory evidence that the alterations in mutant GAD 65 derive from incorrect base-pair incorporation during the PCR reaction. Notably three of the amino-acid substitutions, at positions 247 (mutation B), 425 (mutation C) and 574 (mutation D) are also conserved in the related human isoform, GAD 67 [2, 3] ; furthermore, all four altered residues in the mutant are conserved in the murine and porcine GAD 65 [41, 42] , suggesting important roles in protein folding or function.
Binding of serum antibodies to mutant GAD 65 . When binding of GAD 65 antibody-positive sera from newonset Type I diabetic patients to mutant GAD 65 / ABCD and wild-type GAD 65 was compared, a striking difference was apparent in which substantially lower binding to the mutant was observed for all sera (group mean mutant GAD 65 = 1380 cpm, wildtype GAD 65 = 6147 cpm) (p < 0.0001) (Fig. 2) . No such difference between the binding to mutant GAD 65 /ABCD and wild-type GAD 65 was observed, however, in sera from APS patients (group mean mutant GAD 65 = 5514 cpm, wild-type GAD 65 = 6760 cpm) (p > 0.05) or SMS patients (group mean mutant GAD 65 = 6538 cpm, wild-type GAD 65 = 5904 cpm) (p > 0.05). The data indicate that one or more of the amino-acid alterations in mutant GAD 65 /ABCD results in a statistically significant alteration in the binding of the majority of serum antibodies from Type I diabetic patients. The titres of anti-GAD 65 antibodies in APS and SMS patients are considerably higher than those in sera from Type I diabetic patients [17±20]. To exclude the possibility that higher titres of anti-GAD 65 antibodies in APS and SMS sera were responsible for the binding to mutant GAD 65 / ABCD, we diluted APS and SMS sera so that they precipitated similar counts of translated wild-type GAD 65 to those precipitated by Type I diabetic sera. Immunoprecipitation analyses of wild-type GAD 65 (U), mutant GAD 65 /ABCD (k) and GAD 67 (X) with GAD 65 antibody sera from new-onset Type I diabetic, APS and SMS patients using 35 S-methionine-labelled, translated proteins. Binding of individual sera from different patient groups to various GAD proteins was analysed using the Mann-Whitney U test. The bars represent the group mean values for patients sera precipitated with the translated proteins. The binding of Type I diabetic sera to mutant GAD 65 /ABCD is significantly reduced compared with the reactivity with wild-type GAD 65 . There was no significant difference in the binding of GAD 65 -positive APS and SMS patients sera with the mutant and wild-type GAD 65 These diluted sera still reacted with the mutant GAD 65 /ABCD showing that this effect was not related to antibody titres (not shown). The binding of sera to GAD 67 was also assessed. Sera from Type I diabetic patients showed weak binding to GAD 67 and no statistically significant correlation was observed to levels of binding to either wild-type GAD 65 or mutant GAD 65 /ABCD. In contrast, sera from APS and SMS patients showed levels of binding to GAD 67 similar to wild-type GAD 65 (Fig. 2) .
Effect of reversion of single amino-acid replacements of mutant GAD 65 /ABCD to wild-type residue. To assess the amino acid(s) in mutant GAD 65 /ABCD responsible for the loss of binding of GAD 65 antibodies in Type I diabetic sera, each of the four mutant amino acids was individually reverted back to wild-type residue, creating four new mutants termed mutant GAD 65 /BCD, GAD 65 /ACD, GAD 65 /ABD and GAD 65 /ABC. Translation products from all mutants were found to co-migrate with wild-type GAD 65 in SDS polyacrylamide gel electrophoresis (not shown). Binding of sera from Type I diabetic patients showed higher levels of binding to mutant GAD 65 /ACD (mean = 5000 cpm, p < 0.0001) and mutant GAD 65 / ABC (mean = 5483, p < 0.0001) compared with mutant GAD 65 /ABCD (Fig. 3) . Binding to mutant GAD 65 /BCD (mean = 1571, p > 0.05) and mutant GAD 65 /ABD (mean = 1210, p > 0.05) was, however, similar to mutant GAD 65 /ABCD (Fig. 3) . The higher levels of antibody binding from Type I diabetic sera observed when either residues B or D were reverted to wild-type residues suggests that mutations B and D were responsible for the loss of antibody reactivity to mutant GAD 65 /ABCD; in contrast, mutations A or C have minimal influence on antibody binding in the mutant GAD 65 /ABCD.
To focus on the critical roles of mutations B and D in antibody binding from Type I diabetic sera, new mutants were generated which contained only these mutations either singly or in combination, i. e. mutant GAD 65 /B, GAD 65 /D, GAD 65 /BD and were used in immunoprecipitation experiments with Type I diabetic sera. The binding of sera to mutant GAD 65 /BD was similar to that observed to mutant GAD 65 / ABCD whereas binding to mutant GAD 65 /B and GAD 65 /D was statistically significantly higher, confirming the importance of mutations in residues B or D for loss of antibody binding (data not shown).
Binding of hmABs to single and double amino-acid mutants of GAD 65 . As the GAD 65 autoantibodies in Type I diabetic sera are heterogeneous and recognise a variety of conformational-dependent determinants on GAD 65 , we used hmABs to GAD 65 to determine the role of mutations B and D in maintaining the integrity of conformational-dependent regions in GAD 65 . A panel of 11 hmABs, where all (except MICA 2) are dependent on recognition of different discontinous determinants on GAD 65 , were used [27±33, 43] . None of the hmABs react with GAD 67 [28, 29, 31] . The binding of the hmABs with the mutant GAD 65 /ABCD was either abolished (DP A, DP B, DP D and MICA 3) ( < 10 % binding of wild-type GAD 65 binding) or statistically significantly reduced (MICA 1, MICA 2, MICA 4, MICA 6, DP C, b78 and b96) (10±25 % binding of wild-type GAD 65 ). There was similar reduced binding to the double amino-acid mutant, GAD 65 /BD with all the hmABs (Fig. 4) . Analysis of the binding to the single aminoacid mutants, GAD 65 /B and GAD 65 /D showed two patterns of binding. All the hmABs show reactivity with the mutant GAD 65 /B and thus are not influenced by the single amino-acid mutation B in GAD 65 . In contrast, the binding to the other single amino-acid mutant, GAD 65 /D with MICA 1 and DP A was statistically significantly effected; MICA 3 showed reduced reactivity with this mutant. Notably, all these three hmABs are dependent on C-terminal epitopes of GAD 65 [33] . The binding of the remaining hmABs with the mutant GAD 65 /D, including other C-terminal-directed hmABs such as MICA 2 and b78, was not significantly effected ( > 60 % binding of wild-type GAD 65 ) (Fig. 4) . In summary, all eleven hmABs to GAD 65 show a loss of binding to mutant Expression of recombinant mutant GAD 65 . The mutants, GAD 65 /ABCD, GAD 65 /BD and GAD 65 /D were expressed as recombinant proteins with baculovirus in insect cells. All mutant GAD 65 recombinant proteins co-migrated in SDS polyacrylamide gels with the control, wild-type GAD 65 expressed in insect cells (not shown). None of the mutants showed decarboxylase enzymatic activity; replacement of residues A, B, C and D in the mutant with those present in wild-type GAD 65 led to restoration of decarboxylase activity, which matched the control GAD 65 expressed in insect cells [37] (not shown).
Discussion
Our study reports on a fortuitous finding on a mutant GAD 65 that arose as a result of random mutations during PCR cloning of the molecule. The mutant GAD 65 arose as a result of fortuitous incorrect base incorporations due to the use of Taq polymerase [40] . There are differences between the antibody specificities to GAD 65 present in new-onset Type I diabetic patients and those in APS and SMS patients, with the former antibodies recognising predominantly conformational-dependent epitopes on GAD 65 . [ bodies from new-onset Type I diabetic sera to the mutant GAD 65 suggests that the mutations probably effect the surface conformation and hence the three-dimensional folding of the molecule. The replacement of two residues present in the mutant GAD 65 , Asn247 (residues B) and Leu574 (residue D) was necessary to restore the binding of the autoantibodies of Type I diabetic sera, indicating the crucial nature of these two amino acids in maintaining the structural integrity of GAD 65 .
It was remarkable that two single amino-acid replacements in GAD 65 were able to discriminate the multiple antibody specificities to GAD 65 present in sera from Type I diabetic patients from those of APS and SMS sera. The preferential binding of GAD 65 antibodies in APS and SMS sera with the mutant GAD 65 was not related to the lower antibody titres generally found in Type I diabetic sera [17±20]. To simplify the complex patterns of serum anti-GAD 65 antibody specificities, the role of the two replacements was clarified using hmABs to GAD 65 . The finding that all eleven hmABs used in this study, which recognise different determinants localised to the N-region, C-region and the middle region of GAD 65 [28±33], loose their binding to the double mutant Asn247Ser and Leu574Pro suggests that the two repacements have a considerable effect on the overall surface conformation of the entire molecule.
The single amino-acid replacements at residues 247 (position B) or 574 (position D) of GAD 65 was found to influence the binding of the hmABs differentially. Whereas the replacement of residue 247 was found to be silent in terms of reactivity of the hmABs, the replacement of residue 574 influenced the binding of some hmABs from the panel, including MICA 1, MICA 3 and DP-A. All these three hmABs are directed to the C-terminal region of GAD 65 [33] , but notably other C-terminal-directed hmABs such as MICA 2 and b78 [30±33], were not affected in their reactivity to the single amino-acid replacement in the mutant GAD 65 . Recent mapping of the determinants recognised by MICA 1, MICA 3 and DP-A on GAD 65 indicate that they recognise three distinct, but similar, determinants which are dependent on residues 483±499 and residues 556±585 [33] , whereas the determinants recognised by MICA 2 and b78 reside in distinct residues 512±540 and 514±570, respectively [32, 43] . It is likely that residue 574 forms a contact amino acid for MICA 1, MICA 3 and/or DP-A or it has an effect on the conformation that is localised to the extreme C-terminal region of the molecule without affecting the nearby regions of amino acids 512±540 recognised by MICA 2 and b78. Other single amino acid substitutions in GAD 65 have been described but their effects appear to be limited to influencing the binding of some hmABs [33] , as described above for residue 574. A three-dimensional model of the middle and the C-terminal domain of the GAD 65 dimer has been constructed based on structure modelling from other decarboxylases whose structure is known [33] . The model indicates that the middle and the C-terminal regions form two very separate folding domains in the GAD 65 model. Notably, the two mutations identified in this study that lead to destabilisation of the GAD 65 structure reside in predicted helices (helix I and helix T) which are buried in the two domains [33] , raising the possibility that the simultaneous disruption of both the folded domains leads to total destabilisation of the GAD 65 structure whereas single replacement of these residues either has minimal (residue 247) or limited (residue 574) local conformational effects on the molecule.
The concerted effect of two amino acids Asn-247 and Leu-574 in GAD 65 is essential for maintenance of the conformational determinants recognised by anti-GAD65 autoantibodies directed to a variety of discontinous epitopes, as well as the maintainance of functional enzymatic activity of the molecule. The replacements of these two residues could be useful in discriminating autoimmune sera from Type I diabetic patients from those of APS and SMS by immunoprecipitation assay. In conjunction with GAD 67 precipitation, ambiguous sera could also be confirmed with the use of the two mutants. It is also possible that some changes in epitope patterns of anti-GAD 65 antibodies during progression to disease activity in Type I diabetes could be monitored with the two mutants [44] .
